134 related articles for article (PubMed ID: 24684640)
1. Descriptive review and analysis of immunoglobulin utilization management from 2,548 prior authorization requests.
Tonkovic B; Rutishauser LK
J Manag Care Spec Pharm; 2014 Apr; 20(4):357-67. PubMed ID: 24684640
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Drug use evaluation of tamoxifen focusing on off-label use in a managed care population in Israel.
Kahan NR; Waitman DA; Blackman S; Vardy DA
J Manag Care Pharm; 2010 Jun; 16(5):355-9. PubMed ID: 20518588
[TBL] [Abstract][Full Text] [Related]
4. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. Translating clinical guidelines into practice: the effective and appropriate use of human growth hormone.
Navarro R; Dunn JD; Lee PA; Owens GM; Rapaport R
Am J Manag Care; 2013 Nov; 19(15 Suppl):s281-9. PubMed ID: 24494610
[TBL] [Abstract][Full Text] [Related]
7. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
Bowlus CL; Kenney JT; Rice G; Navarro R
J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
[TBL] [Abstract][Full Text] [Related]
8. Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence.
Czaja AS; Valuck R
Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):997-1004. PubMed ID: 22760843
[TBL] [Abstract][Full Text] [Related]
9. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
[TBL] [Abstract][Full Text] [Related]
10. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Bergeson JG; Worley K; Louder A; Ward M; Graham J
J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
[TBL] [Abstract][Full Text] [Related]
11. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
[TBL] [Abstract][Full Text] [Related]
12. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Chen DT; Wynia MK; Moloney RM; Alexander GC
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
[TBL] [Abstract][Full Text] [Related]
13. Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study.
Clements KM; Clark RE; Lavitas P; Kunte P; Graham CS; O'Connell E; Lenz K; Jeffrey P
J Manag Care Spec Pharm; 2016 Jun; 22(6):714-722b. PubMed ID: 27231798
[TBL] [Abstract][Full Text] [Related]
14. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
15. Dalfampridine prior authorization program: a cohort study.
Gleason PP; Phillips J; Fenrick BA; Delgado-Riley A; Starner CI
J Manag Care Pharm; 2013; 19(1):18-25. PubMed ID: 23383704
[TBL] [Abstract][Full Text] [Related]
16. No. 385-Indications for Pelvic Examination.
Evans D; Goldstein S; Loewy A; Altman AD
J Obstet Gynaecol Can; 2019 Aug; 41(8):1221-1234. PubMed ID: 31331610
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
[TBL] [Abstract][Full Text] [Related]
18. Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.
Li E; Lobaina E
J Manag Care Spec Pharm; 2017 Dec; 23(12):1227-1232. PubMed ID: 29172978
[TBL] [Abstract][Full Text] [Related]
19. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
